Ni Xiao-Chun, Yi Yong, Fu Yi-Peng, He Hong-Wei, Cai Xiao-Yan, Wang Jia-Xing, Zhou Jian, Cheng Yun-Feng, Jin Jian-Jun, Fan Jia, Qiu Shuang-Jian
From the Liver Cancer Institute, Zhongshan Hospital (X-CN, YY, Y-PF, H-WH, X-YC, J-XW, JZ, JF, S-JQ); Shanghai Medical School, Fudan University (X-CN, YY, Y-PF, H-WH, X-YC, J-XW, JZ, JF, S-JQ); Key Laboratory for Carcinogenesis and Cancer Invasion, The Chinese Ministry of Education, Shanghai, People's Republic of China (X-CN, YY, Y-PF, H-WH, X-YC, J-XW, JZ, JF, S-JQ); and Biomedical Research Center, Zhongshan Hospital, Fudan University, Shanghai, 200032, People's Republic of China (Y-FC, J-JJ, S-JQ).
Medicine (Baltimore). 2015 Sep;94(36):e1486. doi: 10.1097/MD.0000000000001486.
There is increasing and consistent evidence concerning the association of systemic inflammation and poor outcome in patients with hepatocellular carcinoma (HCC). The aim of this study was to identify a superior inflammation-based prognostic scoring system for patients with HCC undergoing hepatectomy.We analyzed two independent cohorts of a total of 723 patients with HCC who underwent radical surgery between 2010 and 2012. The prognostic value of the inflammation scores, including the Glasgow Prognostic Score (GPS), modified GPS (mGPS), neutrophil-to-lymphocyte ratio, platelet lymphocyte ratio, prognostic index, and prognostic nutritional index, as well as the Barcelona Clinic Liver Cancer and Cancer of the Liver Italian Program staging systems was analyzed in a test cohort of 367 patients and validated in a validation cohort of 356 patients.A high score with the mGPS was associated with large tumor size, vascular invasion, and advanced clinical stage. Multivariate analysis showed that the mGPS was independently associated with overall survival and disease-free survival, and had a higher area under the curve value in comparison with other inflammation-based scores.The results of this study demonstrated that the mGPS is an independent marker of poor prognosis in patients with resectable HCC and is superior to other inflammation-based scores.
越来越多且一致的证据表明,系统性炎症与肝细胞癌(HCC)患者的不良预后相关。本研究的目的是为接受肝切除术的HCC患者确定一种基于炎症的更优预后评分系统。我们分析了2010年至2012年间接受根治性手术的总共723例HCC患者的两个独立队列。在367例患者的测试队列中分析了炎症评分(包括格拉斯哥预后评分(GPS)、改良GPS(mGPS)、中性粒细胞与淋巴细胞比值、血小板淋巴细胞比值、预后指数和预后营养指数)以及巴塞罗那临床肝癌和意大利肝癌项目分期系统的预后价值,并在356例患者的验证队列中进行了验证。mGPS高分与肿瘤体积大、血管侵犯和临床分期进展相关。多因素分析表明,mGPS与总生存期和无病生存期独立相关,并且与其他基于炎症的评分相比,其曲线下面积值更高。本研究结果表明,mGPS是可切除HCC患者预后不良的独立标志物,并且优于其他基于炎症的评分。